From The Legacy

Credit Suisse lowered shares of WuXi PharmaTech (Cayman) (NYSE:WX) from an outperform rating to a neutral rating in a report released on Thursday, TheFlyOnTheWall.com reports.

Credit Suisse has also updated their ratings on a number of other stocks in the last week. The firm reiterated its restricted rating on shares of Rexam PLC. Also, Credit Suisse reiterated its restricted rating on shares of Rexam PLC. Finally, Credit Suisse reiterated its underperform rating on shares of Standard Chartered PLC. They have a GBX 880 ($13.26) price target on that stock.

Other equities research analysts have also recently issued reports about the stock. Analysts at Morgan Stanley reiterated an overweight rating and set a $42.00 price target on shares of WuXi PharmaTech (Cayman) in a research note on Tuesday. Separately, analysts at Goldman Sachs downgraded shares of WuXi PharmaTech (Cayman) from a conviction-buy rating to a neutral rating and lowered their price target for the stock from $44.50 to $39.50 in a research note on Friday, March 6th. Four investment analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. The stock presently has an average rating of Hold and an average target price of $40.25.

Shares of WuXi PharmaTech (NYSE:WX) traded down 0.60% during mid-day trading on Thursday, hitting $36.74. 177,672 shares of the company’s stock traded hands. WuXi PharmaTech has a 52 week low of $29.84 and a 52 week high of $42.31. The stock has a 50-day moving average of $40. and a 200-day moving average of $36.. The company has a market cap of $2.58 billion and a price-to-earnings ratio of 23.09.

WuXi PharmaTech (Cayman) (NYSE:WX) last posted its quarterly earnings results on Thursday, March 5th. The company reported $0.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.53 by $0.02. The company had revenue of $190.60 million for the quarter, compared to the consensus estimate of $189.54 million. During the same quarter in the previous year, the company posted $0.53 earnings per share. Analysts expect that WuXi PharmaTech will post $1.81 EPS for the current fiscal year.

WuXi PharmaTech (NYSE:WX) Inc (WuXi) is a pharmaceutical, biotechnology and medical device research and development (R&D) outsourcing company, with operations in People’s Republic of China and the United States. The Company provides a portfolio of laboratory and manufacturing services throughout the R&D process to its customers, which include the world’s pharmaceutical, biotechnology and medical device companies.

For more: http://www.lulegacy.com/2015/03/12/wuxi-pharmatech-cayman-lowered-to-neutral-at-credit-suisse-wx/